Found: 12
Select item for more details and to access through your institution.
Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 3, p. 480, doi. 10.1177/13524585211038291
- By:
- Publication type:
- Article
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
- Published in:
- Muscle & Nerve, 2021, v. 64, n. 6, p. 662, doi. 10.1002/mus.27422
- By:
- Publication type:
- Article
Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
- Published in:
- Annals of Clinical & Translational Neurology, 2021, v. 8, n. 7, p. 1398, doi. 10.1002/acn3.51376
- By:
- Publication type:
- Article
Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
- Published in:
- Annals of Clinical & Translational Neurology, 2020, v. 7, n. 8, p. 1327, doi. 10.1002/acn3.51121
- By:
- Publication type:
- Article
Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder.
- Published in:
- Annals of Neurology, 2023, v. 93, n. 6, p. 1053, doi. 10.1002/ana.26626
- By:
- Publication type:
- Article
Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study.
- Published in:
- Frontiers in Neurology, 2020, v. 11, p. N.PAG, doi. 10.3389/fneur.2020.556104
- By:
- Publication type:
- Article
(DXT66) Clinical Benefits of Eculizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 40
- By:
- Publication type:
- Article
(DXT52) Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: The Phase 3 PREVENT Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 34
- By:
- Publication type:
- Article
(DXT41) Eculizumab Benefits a Broad Range of Patients with Aquaporin-4 Antibody--Positive Neuromyelitis Optica Spectrum Disorder: The Phase 3 PREVENT Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 30
- By:
- Publication type:
- Article
(DXT31) Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Neuromyelitis Optica Spectrum Disorder: Phase 3 PREVENT Study.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 26
- By:
- Publication type:
- Article
(DXT14) Long-Term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 20
- By:
- Publication type:
- Article